Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 37, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/s13046-018-0719-1
Keywords
-
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro [18637, 16910] Funding Source: Medline
Ask authors/readers for more resources
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available